Nina Norden1, Erik O Lundin1, Eva Hagberg2,3, Sinsia A Gao2, Mathias Hård Af Segerstad1, Bengt Nellgård1, Keti Dalla1. 1. Department of Anaesthesia and Intensive Care Unit, Institute of Clinical Sciences, Sahlgrenska Academy at The University of Gothenburg Gothenburg, Sweden. 2. Department of Clinical Physiology, Institute of Medicine, Sahlgrenska Academy at The University of Gothenburg Gothenburg, Sweden. 3. Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg Sweden.
Abstract
INTRODUCTION: In this prospective, observational study, we have evaluated right (RV) and left (LV) ventricular function with echocardiography and correlated it to the levels of biomarkers, hs-TNT, NT-pro-BNP, D-dimer and fibrinogen. In a subgroup, we have evaluated the effect of inhaled milrinone on RV afterload and function. METHODS: Thirty-one ICU patients with COVID-19 in need of mechanical ventilation and norepinephrine infusion were prospectively included. Hemodynamic and respiratory variables were measured at the time of the echocardiographic examination and biomarkers were obtained on arrival at the ICU and then followed up routinely. Eight patients received inhaled aerosolized milrinone at a dose of 2.5 mg/hour. RESULTS: The most common echocardiographic pattern was RV dilation with or without systolic dysfunction, which was found in 62% of patients. Pulmonary acceleration time was abnormal in 55% and indices of RV systolic function, such as fractional area of change, RV strain, were abnormal in 30% and 31% of patients respectively. A cardiac index of < 2.5 l/min*m2 was seen in 58% of the patients. Left ventricular ejection fraction and global left ventricular strain were impaired in 10% and 16% respectively. The correlation between echocardiographic variables and cardiac biomarkers was poor. RV afterload correlated well to the levels of D-dimer. Milrinone inhalation did not improve RV function or afterload. CONCLUSION: RV dysfunction was the most common finding. The poor correlation to cardiac biomarkers argues against extensive myocardial involvement. The lack of improvement in RV function after milrinone inhalation suggests that the most likely cause of RV dysfunction is increased RV afterload caused by pulmonary thrombosis/embolism. AJCD
INTRODUCTION: In this prospective, observational study, we have evaluated right (RV) and left (LV) ventricular function with echocardiography and correlated it to the levels of biomarkers, hs-TNT, NT-pro-BNP, D-dimer and fibrinogen. In a subgroup, we have evaluated the effect of inhaled milrinone on RV afterload and function. METHODS: Thirty-one ICU patients with COVID-19 in need of mechanical ventilation and norepinephrine infusion were prospectively included. Hemodynamic and respiratory variables were measured at the time of the echocardiographic examination and biomarkers were obtained on arrival at the ICU and then followed up routinely. Eight patients received inhaled aerosolized milrinone at a dose of 2.5 mg/hour. RESULTS: The most common echocardiographic pattern was RV dilation with or without systolic dysfunction, which was found in 62% of patients. Pulmonary acceleration time was abnormal in 55% and indices of RV systolic function, such as fractional area of change, RV strain, were abnormal in 30% and 31% of patients respectively. A cardiac index of < 2.5 l/min*m2 was seen in 58% of the patients. Left ventricular ejection fraction and global left ventricular strain were impaired in 10% and 16% respectively. The correlation between echocardiographic variables and cardiac biomarkers was poor. RV afterload correlated well to the levels of D-dimer. Milrinone inhalation did not improve RV function or afterload. CONCLUSION:RV dysfunction was the most common finding. The poor correlation to cardiac biomarkers argues against extensive myocardial involvement. The lack of improvement in RV function after milrinone inhalation suggests that the most likely cause of RV dysfunction is increased RV afterload caused by pulmonary thrombosis/embolism. AJCD
Authors: Maximilian Ackermann; Stijn E Verleden; Mark Kuehnel; Axel Haverich; Tobias Welte; Florian Laenger; Arno Vanstapel; Christopher Werlein; Helge Stark; Alexandar Tzankov; William W Li; Vincent W Li; Steven J Mentzer; Danny Jonigk Journal: N Engl J Med Date: 2020-05-21 Impact factor: 91.245
Authors: Jason P Schott; Amy N Mertens; Richard Bloomingdale; Thomas F O'Connell; Michael J Gallagher; Simon Dixon; Amr E Abbas Journal: Echocardiography Date: 2020-09-19 Impact factor: 1.724
Authors: Michele D'Alto; Alberto M Marra; Sergio Severino; Andrea Salzano; Emanuele Romeo; Rosanna De Rosa; Francesca Maria Stagnaro; Gianpiero Pagnano; Raffaele Verde; Patrizia Murino; Andrea Farro; Giovanni Ciccarelli; Maria Vargas; Giuseppe Fiorentino; Giuseppe Servillo; Ivan Gentile; Antonio Corcione; Antonio Cittadini; Robert Naeije; Paolo Golino Journal: Crit Care Date: 2020-11-30 Impact factor: 9.097
Authors: Summer Chavez; William J Brady; Michael Gottlieb; Brandon M Carius; Stephen Y Liang; Alex Koyfman; Brit Long Journal: Am J Emerg Med Date: 2022-05-14 Impact factor: 4.093